IN2014DN08969A - - Google Patents

Info

Publication number
IN2014DN08969A
IN2014DN08969A IN8969DEN2014A IN2014DN08969A IN 2014DN08969 A IN2014DN08969 A IN 2014DN08969A IN 8969DEN2014 A IN8969DEN2014 A IN 8969DEN2014A IN 2014DN08969 A IN2014DN08969 A IN 2014DN08969A
Authority
IN
India
Prior art keywords
hypophosphatemic rickets
pyrimid
hyp
piperazin
phenylamino
Prior art date
Application number
Inventor
Michaela Kneissel
Vito Guagnano
Porta Diana Graus
Simon Wöhrle
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN08969A publication Critical patent/IN2014DN08969A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

The present invention relates generally wild-type - vehicle Hyp - vehicle Hyp - BGJ398 to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-l-{6-[4-(4- ethyl-piperazin- 1-yl)-phenylamino]-pyrimid-4-yl} -1- methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition com prising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-l-{6- [4-(4-ethyl-piperazin-l-yl)-phenylamino]-pyrimid-4- yl} -1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recess ive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.
IN8969DEN2014 2012-03-30 2013-03-29 IN2014DN08969A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261617889P 2012-03-30 2012-03-30
PCT/EP2013/056811 WO2013144339A1 (en) 2012-03-30 2013-03-29 Fgfr inhibitor for use in the treatment of hypophosphatemic disorders

Publications (1)

Publication Number Publication Date
IN2014DN08969A true IN2014DN08969A (en) 2015-05-22

Family

ID=47998482

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8969DEN2014 IN2014DN08969A (en) 2012-03-30 2013-03-29

Country Status (11)

Country Link
US (3) US20150072019A1 (en)
EP (1) EP2830626B1 (en)
JP (1) JP6190871B2 (en)
KR (1) KR102126092B1 (en)
CN (2) CN104321058A (en)
AU (1) AU2013241664B2 (en)
CA (1) CA2866229C (en)
IN (1) IN2014DN08969A (en)
MX (1) MX354783B (en)
RU (1) RU2643326C2 (en)
WO (1) WO2013144339A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
AU2013287176C1 (en) 2012-06-13 2023-01-19 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
UA120087C2 (en) 2013-04-19 2019-10-10 Інсайт Холдинґс Корпорейшн Bicyclic heterocycles as fgfr inhibitors
EA028614B1 (en) * 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
ES2751669T3 (en) 2015-02-20 2020-04-01 Incyte Corp Bicyclic heterocycles as FGFR inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
WO2016189472A1 (en) * 2015-05-28 2016-12-01 Novartis Ag Fgfr inhibitor for use in the treatment of the phosphaturic mesenchymal tumor
AU2016296997B2 (en) * 2015-07-20 2020-07-09 Taipei Medical University Chlorobenzene substituted azaaryl compounds
AU2016300175A1 (en) * 2015-07-24 2018-03-01 Debiopharm International Sa FGFR expression and susceptibility to an FGFR inhibitor
AU2018206372B2 (en) 2017-01-06 2020-10-08 Lemonex Inc. Composition for preventing or treating metastatic ovarian cancer, endometrial cancer or breast cancer
WO2018128510A1 (en) * 2017-01-06 2018-07-12 주식회사 레모넥스 Composition for preventing or treating metastatic ovarian cancer, endometrial cancer or breast cancer
US10886468B2 (en) 2017-04-14 2021-01-05 Sakai Display Products Corporation Manufacturing method and manufacturing apparatus for organic EL display device
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
JP2021523121A (en) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Solid form of FGFR inhibitor and its preparation process
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
JP2022526713A (en) 2019-03-21 2022-05-26 オンクセオ Dbait molecule in combination with a kinase inhibitor for the treatment of cancer
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (en) 2019-10-14 2022-10-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114761006A (en) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) Methods of treating cancer resistant to kinase inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
BR112022010664A2 (en) 2019-12-04 2022-08-16 Incyte Corp DERIVATIVES OF A FGFR INHIBITOR
WO2021119108A1 (en) * 2019-12-09 2021-06-17 Cedars-Sinai Medical Center Use of fgfr inhibitors for treatment of idiopathic short stature
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR126102A1 (en) 2021-06-09 2023-09-13 Incyte Corp TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354949A4 (en) 2000-12-26 2004-05-19 Chugai Pharmaceutical Co Ltd Human fgf23 protein mutant lowering blood phosphorus level
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1882475A1 (en) * 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
RU2010148531A (en) * 2008-04-29 2012-06-10 Новартис АГ (CH) METHODS FOR MONITORING KINASE KINASE ACTIVITY RECEPTOR OF FIBROBLAST GROWTH FACTOR RECEPTOR AND APPLICATION OF THE SPECIFIED METHODS
KR20120101367A (en) * 2009-10-30 2012-09-13 노파르티스 아게 N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
AR079257A1 (en) 2009-12-07 2012-01-04 Novartis Ag CRYSTAL FORMS OF 3- (2,6-DICLORO-3-5-DIMETOXI-PHENYL) -1- {6- [4- (4-ETIL-PIPERAZIN-1-IL) -PENYL-AMINO] -PIRIMIDIN-4- IL} -1-METHYL-UREA AND SALTS OF THE SAME
EP2512476A1 (en) * 2009-12-18 2012-10-24 Novartis AG Method for treating haematological cancers
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3

Also Published As

Publication number Publication date
US20150072019A1 (en) 2015-03-12
KR20140145133A (en) 2014-12-22
US20210308132A1 (en) 2021-10-07
RU2014143517A (en) 2016-05-27
RU2643326C2 (en) 2018-01-31
EP2830626B1 (en) 2019-01-02
CN109718239A (en) 2019-05-07
JP2015511621A (en) 2015-04-20
US10028955B2 (en) 2018-07-24
MX2014011841A (en) 2015-02-10
AU2013241664A1 (en) 2014-10-02
MX354783B (en) 2018-03-21
JP6190871B2 (en) 2017-08-30
US20170007606A1 (en) 2017-01-12
WO2013144339A1 (en) 2013-10-03
KR102126092B1 (en) 2020-06-24
AU2013241664B2 (en) 2016-05-19
CN104321058A (en) 2015-01-28
CA2866229C (en) 2020-09-15
CA2866229A1 (en) 2013-10-03
EP2830626A1 (en) 2015-02-04

Similar Documents

Publication Publication Date Title
IN2014DN08969A (en)
MX2012006562A (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[ 4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl -urea and salts thereof.
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2015006412A (en) Cxcr7 antagonists.
JO3413B1 (en) Naphthyridine derrivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
PH12015502615A1 (en) Chemical compounds
WO2012066578A3 (en) Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
MD20160089A2 (en) Cortistatin analogues and syntheses and uses thereof
UA107806C2 (en) Pterydyny and their use as agrochemicals
MX2011012344A (en) Disaccharin, difumaric acid, di-l-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4- (dimethylamin0)butyl 2- (4- ( (2-amino-4-methyl-6- (pentylamino) pyrimidin- 5 -yl) methyl) phenyl)acetate.
GEP20196982B (en) Pharmaceutical composition containing pyridylamino acetic acid compound
MX2015009465A (en) Chemical compounds.
CO6270323A2 (en) SOLID FORMS OF ACID (S) -2-AMINO-3- (4- (2-AMINO-6 - ((R) -2,2,2-TRIFLUORO- 1- (3'-METOXIBIFENIL-4-IL) ETOXI ) PIRIMIDIN-4-IL) PHENYL) PROPANOIC AND METHODS FOR USE
BR112015024743A2 (en) substituted biaryl compound
CL2011002278A1 (en) Process for the preparation of (e) -n- (4- (3-tert-butyl-5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2h) -yl) -2-methoxystyryl) phenyl) methanesulfonamide or its salt by reduction of the corresponding ethynyl; and the intermediary compounds considered.
MX2013010308A (en) 2,4 substituted pyrimidinediamines for use in discoid lupus.
UA112423C2 (en) Method for the preparation of high-purity pharmaceutical intermediates
PH12014501979A1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
MX2017008430A (en) Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives.
UY34223A (en) FORMULATIONS OF (NEW TRIMETOXIFENILAMINO) PYRIMIDINYL
MX2017001603A (en) Piperazine derivatives as liver x receptor modulators.
MX2014003455A (en) Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands.
PH12015500322A1 (en) Tris(hetero)arylpyrazoles and use thereof
MX2010011006A (en) New salt of a pyrimidin derivative.
GB201004677D0 (en) New salt